SETBP1 and myeloproliferative neoplasm: Recurrent mutations of SETBP1 have been identified in up to one third of aCML patients as compared to 10% only of MDS/MPN-U and 6–15% of CMML, and occasionally in JMML or AML secondary to MPN or MDS [27].